EX-99.2 3 nept-99_2.htm EX-99.2 nept-40f_20180331.htm

Exhibit 99.2

Consolidated Financial Statements of

neptune technologies & Bioressources inc.

For the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

KPMG LLP

Telephone

(514) 840-2100

600 de Maisonneuve Blvd. West

Fax

(514) 840-2187

Suite 1500, Tour KPMG

Internet

www.kpmg.ca

Montréal (Québec)  H3A 0A3

 

 

Canada

 

 

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of Neptune Technologies & Bioressources Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Neptune Technologies & Bioressources Inc. (the "Entity"), which comprise the consolidated statements of financial position as at March 31, 2018 and March 31, 2017, the consolidated statements of earnings and comprehensive income, changes in equity and cash flows for the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017, and the related notes, comprising a summary of significant accounting policies and other explanatory information (collectively referred to as the "consolidated financial statements").

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Entity as at March 31, 2018 and March 31, 2017, and its consolidated financial performance and its consolidated cash flows for the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017 in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Report on Internal Control Over Financial Reporting

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Entity’s internal control over financial reporting as of March 31, 2018, based on the criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated June 5, 2018 expressed an unqualified (unmodified) opinion on the effectiveness of the Entity’s internal control over financial reporting.

Basis for Opinion

A - Management’s Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

 

KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG
network of independent member firms affiliated with KPMG International Cooperative
("KPMG International"), a Swiss entity.
KPMG Canada provides services to KPMG LLP.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 2

 

B - Auditors’ Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB").  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement, whether due to error or fraud. Those standards also require that we comply with ethical requirements, including independence. We are required to be independent with respect to the Entity in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We are a public accounting firm registered with the PCAOB.

An audit includes performing procedures to assess the risks of material misstatements of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included obtaining and examining, on a test basis, audit evidence regarding the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.  In making those risk assessments, we consider internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances.

An audit also includes evaluating the appropriateness of accounting policies and principles used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a reasonable basis for our audit opinion.

 

We have served as the Entity's auditor since 2007.

 

June 5, 2018

Montréal, Canada

 

 

 

*CPA auditor, CA, public accountancy permit No. A119178

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

KPMG LLP

Telephone

(514) 840-2100

600 de Maisonneuve Blvd. West

Fax

(514) 840-2187

Suite 1500, Tour KPMG

Internet

www.kpmg.ca

Montréal (Québec)  H3A 0A3

 

 

Canada

 

 

 

 

 

 

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Neptune Technologies & Bioressources Inc.

Opinion on Internal Control Over Financial Reporting

We have audited Neptune Technologies & Bioressources Inc.’s (the "Entity") internal control over financial reporting as of March 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

In our opinion, the Entity maintained, in all material respects, effective internal control over financial reporting as of March 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Report on the Consolidated Financial Statements

We also have audited, in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated financial statements of the Entity, which comprise the consolidated statements of financial position as of March 31, 2018 and 2017, and the consolidated statements of earnings and comprehensive income, changes in equity and cash flows for the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017, and the related notes, comprising a summary of significant accounting policies and other explanatory information (collectively referred to as the “consolidated financial statements”) and our report dated June 5, 2018 expressed an unmodified (unqualified) opinion on those consolidated financial statements.

Basis for Opinion

The Entity’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Entity’s internal control over financial reporting based on our audit.

We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Entity in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB and in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada.


 

KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG
network of independent member firms affiliated with KPMG International Cooperative
("KPMG International"), a Swiss entity.
KPMG Canada provides services to KPMG LLP.

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 2

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

An entity’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. An entity’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the entity; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the entity are being made only in accordance with authorizations of management and directors of the entity; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the entity’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

 

 

 

June 5, 2018

Montréal, Canada

 

 

 

 

 

 

 

 

*CPA auditor, CA, public accountancy permit No. A119178

 

 

 


 

neptune technologies & bioressources inc.

Consolidated Financial Statements

For the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017

Financial Statements

 

 

 

 

 


 

neptune technologies & bioressources inc.

Consolidated Statements of Financial Position

As at March 31, 2018 and 2017

 

 

 

March 31,

 

 

March 31,

 

 

 

2018

 

 

2017

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents (note 24)

 

$

24,287,107

 

 

$

15,802,363

 

Restricted short-term investment (note 24)

 

 

2,350,000

 

 

 

 

Trade and other receivables (note 5)

 

 

5,590,847

 

 

 

13,559,469

 

Tax credits receivable (note 18)

 

 

49,597

 

 

 

139,932

 

Prepaid expenses

 

 

372,944

 

 

 

684,261

 

Inventories (note 6)

 

 

5,261,329

 

 

 

13,242,735

 

Other financial asset (note 21 (a)(iii))

 

 

19,090

 

 

 

 

 

 

 

37,930,914

 

 

 

43,428,760

 

 

 

 

 

 

 

 

 

 

Restricted short-term investments (note 24)

 

 

60,000

 

 

 

2,745,000

 

Property, plant and equipment (note 7)

 

 

41,880,847

 

 

 

45,864,367

 

Intangible assets (note 8)

 

 

5,236,363

 

 

 

11,947,693

 

Goodwill (note 8)

 

 

6,750,626

 

 

 

6,750,626

 

Tax credits recoverable (note 18)

 

 

152,464

 

 

 

152,464

 

Deferred tax assets (note 18)

 

 

 

 

 

265,461

 

Other assets (notes 13 and 21 (a)(i))

 

 

6,585,740

 

 

 

65,745

 

Total assets

 

$

98,596,954

 

 

$

111,220,116

 

 

 

 

 

 

 

 

 

 

Liabilities and Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Trade and other payables (note 9)

 

$

6,747,889

 

 

$

9,993,019

 

Loans and borrowings (note 10)

 

 

4,661,356

 

 

 

7,192,315

 

Deferred revenues

 

 

109,954

 

 

 

549,675

 

 

 

 

11,519,199

 

 

 

17,735,009

 

 

 

 

 

 

 

 

 

 

Deferred lease inducements

 

 

267,101

 

 

 

326,456

 

Long-term payable (note 11)

 

 

249,714

 

 

 

795,072

 

Deferred tax liabilities (note 18)

 

 

27,170

 

 

 

 

Loans and borrowings (note 10)

 

 

 

 

 

15,739,229

 

Unsecured convertible debentures

 

 

 

 

 

1,406,365

 

Other financial liabilities (note 21 (a)(ii) and (iii))

 

 

 

 

 

417,747

 

Total liabilities

 

 

12,063,184

 

 

 

36,419,878

 

 

 

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

 

 

 

Share capital (note 12)

 

 

128,483,507

 

 

 

127,201,343

 

Warrants (note 12 (e))

 

 

648,820

 

 

 

648,820

 

Contributed surplus

 

 

36,355,549

 

 

 

33,335,136

 

Accumulated other comprehensive income (loss)

 

 

525,559

 

 

 

(427,350

)

Deficit

 

 

(79,479,665

)

 

 

(97,010,523

)

Total equity attributable to equity holders of the Corporation

 

 

86,533,770

 

 

 

63,747,426

 

 

 

 

 

 

 

 

 

 

Non-controlling interest (note 13)

 

 

 

 

 

7,435,948

 

Subsidiary warrants, options and other equity (note 13)

 

 

 

 

 

3,616,864

 

Total equity attributable to non-controlling interest

 

 

 

 

 

11,052,812

 

Total equity

 

 

86,533,770

 

 

 

74,800,238

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (note 23)

 

 

 

 

 

 

 

 

Total liabilities and equity

 

$

98,596,954

 

 

$

111,220,116

 

 

See accompanying notes to consolidated financial statements.

 

On behalf of the Board:

 

 

 

 

 

/s/ John Moretz

 

/s/ François R. Roy

John Moretz

 

François R. Roy

Chairman of the Board

 

Director

 

 

 

1


 

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Statements of Earnings and Comprehensive Income

 

For the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017

 

 

 

 

March 31,

2018

 

 

March 31,

2017

 

 

 

 

(12 months)

 

 

(13 months)

 

Revenue from sales (note 4)

 

$

26,168,469

 

 

$

45,734,361

 

Royalty revenues

 

 

1,477,113

 

 

 

1,083,022

 

Total revenues

 

 

27,645,582

 

 

 

46,817,383

 

 

 

 

 

 

 

 

 

 

 

Cost of sales (note 6)

 

 

(18,944,321

)

 

 

(34,015,571

)

Other cost of sales - impairment loss on inventories (notes 4 et 6)

 

 

(2,376,969

)

 

 

 

 

 

 

 

(21,321,290

)

 

 

(34,015,571

)

Gross margin

 

 

6,324,292

 

 

 

12,801,812

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

(12,395,671

)

 

 

(7,248,873

)

Research tax credits and grants  (note 18)

 

 

(1,751,952

)

 

 

2,408,377

 

 

 

 

 

(14,147,623

)

 

 

(4,840,496

)

Selling, general and administrative expenses

 

 

(14,708,250

)

 

 

(17,060,852

)

Other income - royalty settlement (note 14)

 

 

 

 

 

15,301,758

 

Other income - net gain on sale of assets (note 4)

 

 

23,702,312

 

 

 

 

Income from operating activities

 

 

1,170,731

 

 

 

6,202,222

 

 

 

 

 

 

 

 

 

 

 

Gain on loss of control of subsidiary (note 13)

 

 

8,783,613

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finance income

 

 

227,465

 

 

 

66,536

 

Finance costs (note 16)

 

 

(2,446,279

)

 

 

(2,772,146

)

Change in fair value of derivative assets and liabilities and loss on sale of

   available-for-sale investment (note 21)

 

 

(36,347

)

 

 

(263,135

)

 

 

 

 

(2,255,161

)

 

 

(2,968,745

)

Income before income taxes

 

 

7,699,183

 

 

 

3,233,477

 

 

 

 

 

 

 

 

 

 

 

Income tax recovery (expense) (note 18)

 

 

1,640,200

 

 

 

(2,353,628

)

Net income

 

 

9,339,383

 

 

 

879,849

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income (loss) (that may be reclassified subsequently to net income)

 

 

 

 

 

 

 

 

 

Unrealized gains (losses) on available-for-sale investments (notes 13 and 21 (a)(i))

 

 

544,834

 

 

 

(104,705

)

 

Net change in unrealized gains on derivatives designated as cash flow hedges

   (note 21 (a)(iii))

 

 

26,388

 

 

 

29,751

 

 

Reclassification to net income of accumulated realized gain on available-for-sale

   investment (note 21 (a)(i))

 

 

381,687

 

 

 

 

Total other comprehensive income (loss)

 

 

952,909

 

 

 

(74,954

)

 

 

 

 

 

 

 

 

 

 

Total comprehensive income

 

$

10,292,292

 

 

$

804,895

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to:

 

 

 

 

 

 

 

 

Equity holders of the Corporation

 

$

17,530,858

 

 

$

6,913,228

 

Non-controlling interest (note 13)

 

 

(8,191,475

)

 

 

(6,033,379

)

Net income

 

$

9,339,383

 

 

$

879,849

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income attributable to:

 

 

 

 

 

 

 

 

Equity holders of the Corporation

 

$

18,483,767

 

 

$

6,838,274

 

Non-controlling interest (note 13)

 

 

(8,191,475

)

 

 

(6,033,379

)

Total comprehensive income

 

$

10,292,292

 

 

$

804,895

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted income per share

 

$

0.22

 

 

$

0.09

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average number of common shares (note 19)

 

 

78,599,208

 

 

 

77,945,548

 

Diluted weighted average number of common shares (note 19)

 

 

79,359,296

 

 

 

78,145,887

 

 

See accompanying notes to consolidated financial statements.

 

 

2


NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Statements of Changes in Equity

For the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017

 

 

 

Attributable to equity holders of the Corporation

 

 

Attributable to non-controlling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share Capital

 

 

 

 

 

 

 

 

 

 

other comprehensive

 

 

 

 

 

 

 

 

 

 

Subsidiary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

income (loss)

 

 

 

 

 

 

 

 

 

 

warrants,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number

 

 

Dollars

 

 

Warrants

 

 

Contributed

surplus

 

 

Available-

for-sale

investment

 

 

Cash flow

hedges

 

 

Deficit

 

 

Total

 

 

options

and other

equity

 

 

Non-

controlling

interest

 

 

Total

 

 

Total

equity

 

Balance at March 31, 2017

 

 

77,968,587

 

 

$

127,201,343

 

 

$

648,820

 

 

$

33,335,136

 

 

$

(420,052

)

 

$

(7,298

)

 

$

(97,010,523

)

 

$

63,747,426

 

 

$

3,616,864

 

 

$

7,435,948

 

 

$

11,052,812

 

 

$

74,800,238

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) for the period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17,530,858

 

 

 

17,530,858

 

 

 

 

 

 

(8,191,475

)

 

 

(8,191,475

)

 

 

9,339,383

 

Other comprehensive income for the period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

926,521

 

 

 

26,388

 

 

 

 

 

 

952,909

 

 

 

 

 

 

 

 

 

 

 

 

952,909

 

Total comprehensive income (loss) for the period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

926,521

 

 

 

26,388

 

 

 

17,530,858

 

 

 

18,483,767

 

 

 

 

 

 

(8,191,475

)

 

 

(8,191,475

)

 

 

10,292,292

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Transaction with equity holders recorded

   directly in equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contributions by and distribution to equity

   holders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based payment transactions

   (note 17)

 

 

 

 

 

 

 

 

 

 

 

1,623,145

 

 

 

 

 

 

 

 

 

 

 

 

1,623,145

 

 

 

660,611

 

 

 

 

 

 

660,611

 

 

 

2,283,756

 

Liability settled in shares (note 12 (b))

 

 

630,681

 

 

 

848,070

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

848,070

 

 

 

 

 

 

 

 

 

 

 

 

848,070

 

DSU released (note 12 (c))

 

 

55,944

 

 

 

80,000

 

 

 

 

 

 

(80,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share options exercised (note 12 (d))

 

 

149,000

 

 

 

354,094

 

 

 

 

 

 

(97,478

)

 

 

 

 

 

 

 

 

 

 

 

256,616

 

 

 

 

 

 

 

 

 

 

 

 

256,616

 

Loss of control of subsidiary (note 13)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,739,050

)

 

 

505,077

 

 

 

(2,233,973

)

 

 

(2,233,973

)

Total contributions by and distribution to

   equity holders

 

 

835,625

 

 

 

1,282,164

 

 

 

 

 

 

1,445,667

 

 

 

 

 

 

 

 

 

 

 

 

2,727,831

 

 

 

(2,078,439

)

 

 

505,077

 

 

 

(1,573,362

)

 

 

1,154,469

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in ownership interests in subsidiaries

   that do not result in a loss of control

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expiry of Acasti options and call-options

   (note 13 (i))

 

 

 

 

 

 

 

 

 

 

 

1,466,459

 

 

 

 

 

 

 

 

 

 

 

 

1,466,459

 

 

 

(1,466,459

)

 

 

 

 

 

(1,466,459

)

 

 

 

Exercise of warrants (note 13 (ii))

 

 

 

 

 

 

 

 

 

 

 

155,720

 

 

 

 

 

 

 

 

 

 

 

 

155,720

 

 

 

(71,966

)

 

 

300,496

 

 

 

228,530

 

 

 

384,250

 

Fees related to past financing of Acasti

   (note 13 (iii))

 

 

 

 

 

 

 

 

 

 

 

(52,452

)

 

 

 

 

 

 

 

 

 

 

 

(52,452

)

 

 

 

 

 

(102,011

)

 

 

(102,011

)

 

 

(154,463

)

Convertible debenture interest settled in

    shares (note 13 (iv))

 

 

 

 

 

 

 

 

 

 

 

5,019

 

 

 

 

 

 

 

 

 

 

 

 

5,019

 

 

 

 

 

 

51,965

 

 

 

51,965

 

 

 

56,984

 

Total changes in ownership interest in

   subsidiaries

 

 

 

 

 

 

 

 

 

 

 

1,574,746

 

 

 

 

 

 

 

 

 

 

 

 

1,574,746

 

 

 

(1,538,425

)

 

 

250,450

 

 

 

(1,287,975

)

 

 

286,771

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total transactions with equity holders

 

 

835,625

 

 

 

1,282,164

 

 

 

 

 

 

3,020,413

 

 

 

 

 

 

 

 

 

 

 

 

4,302,577

 

 

 

(3,616,864

)

 

 

755,527

 

 

 

(2,861,337

)

 

 

1,441,240

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2018

 

 

78,804,212

 

 

$

128,483,507

 

 

$

648,820

 

 

$

36,355,549

 

 

$

506,469

 

 

$

19,090

 

 

$

(79,479,665

)

 

$

86,533,770

 

 

$

 

 

$

 

 

$

 

 

$

86,533,770

 

 

See accompanying notes to consolidated financial statements.

3


NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Statements of Changes in Equity, Continued

For the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017

 

 

 

Attributable to equity holders of the Corporation

 

 

Attributable to non-controlling interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share Capital

 

 

 

 

 

 

 

 

 

 

other comprehensive

 

 

 

 

 

 

 

 

 

 

Subsidiary